Medtronic

image54

 Study Shows Improved Quality of Life and Reduced Symptoms In Patients Treated with Medtronic Cryoballoon 

cryoballoon ablation clinical studies
image55

 Treatment with ITB Therapy vs. Oral Medication Shows Quality of Life Improvement, Reduction in Spasticity-Related Pain 

ABOUT ITB THERAPY FOR SEVERE SPASTICITY
image56

 Medtronic Announces One-Month DAPT Clinical Study in the U.S. and Japan with Resolute Onyx DES in High Bleeding Risk Patients 

Resolute Onyx(TM) Drug-Eluting Stent (DES)
image58

 Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure 

eartWare(TM) HVAD(TM) System Only LVAD Approved for Implant via Thoracotomy or Median Sternotomy

Bluetooth® enabled MiniMed(TM) 780G advanced hybrid closed loop (AHCL)

image59

Medtronic Initiates Pivotal Trial for Bluetooth Enabled MiniMed(TM) 780G Advanced Hybrid Closed Loop System Designed to Automate Correction Bolusing

Sat June 8, 2019 1:00 PM|InPublic US|About: MDT

DUBLIN - June 8, 2019 - Medtronic plc (MDT)

Medtronic Initiates Pivotal Trial for Next-Generation Guardian(TM) Continuous Glucose Monitoring Sensor (GLOBE NEWSWIRE via COMTEX) --DUBLIN - June 8, 2019 - Medtronic plc (NYSE:MDT)

abbott

image60

 Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves

MitraClip®
image61

 Abbott's Tendyne mitral valve shows positive effect in global study

TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT
image62

 NEW COVERAGE DECISION EXTENDS ABBOTT'S INNOVATIVE PAIN THERAPY OPTION TO 22 MILLION AMERICANS LIVING WITH CHRONIC PAIN 

Abbott is the only company in the world with FDA and CE Mark approval to offer dorsal root ganglion (DRG) neurostimulation therapy to treat complex nerve pain conditions
image63

 ABBOTT'S FREESTYLE® LIBRE 14 DAY FLASH GLUCOSE MONITORING SYSTEM NOW APPROVED IN U.S. 

FREESTYLE® LIBRE 14 DAY FLASH GLUCOSE MONITORING SYSTEM
image64

 ABBOTT EXPANDS ITS DIRECTIONAL DEEP BRAIN STIMULATION THERAPY BY OFFERING NEW MR-CONDITIONAL LABELING 

Abbott's Infinity™ DBS system
image65

 ABBOTT INTRODUCES BREAKTHROUGH POINT-OF-CARE TEST, THE M-PIMA™ HIV-1/2 VIRAL LOAD (VL), AT AIDS 2018 AMSTERDAM 

m-PIMA™ HIV-1/2 VIRAL LOAD TEST

Abiomed

image66

 Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treate 

Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps
image67

 Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor 

Impella CP® with SmartAssist™ and Optical Sensor
image68

 Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg 

The Impella 5.5 is approved in Europe

Impella 5.0 and Impella LD

image69

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Mon May 13, 2019 12:00 PM|Business Wire|About: ABMD

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed  (ABM

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy DANVERS, Mass.--(BUSINESS WIRE)--May 13, 2019-- Abiomed (NASDAQ:ABMD)
image70

 Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock 

Impella 2.5, Impella CP, Impella 5.0, and Impella LD Catheters, in conjunction with the Automated Impella Controller

illumina

image72

 Illumina Receives Approval of MiSeq™Dx System in China

MiSeq™Dx System
image73

 Thermo Fisher Scientific and Illumina Sign Agreement to Provide Research Market Broader Access to Ion AmpliSeq Technology

AmpliSeq for Illumina – a comprehensive targeted resequencing solutio
image74

 Illumina Launches iSeq 100 Sequencing System

iSeq™ 100 Sequencing System
image75

 Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies

A Diagnostic Version of the Illumina TruSight™ Oncology 500 Assay Will Measure Potentially Predictive Genomic Biomarkers, Including Tumor Mutation Burden

VeriSeq™ NIPT Solution v2

image76

June 04, 2019 09:00 AM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN

Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions

Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing 


Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing SAN DIEGO--(BUSINESS WIRE)--Jun. 4, 2019-- Illumina, Inc. (NASDAQ: ILMN
image77

 Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina and Loxo Oncology Join Forces to Develop Pan-Cancer Companion Diagnostics

Intuitive surgical

image78

 Intuitive Surgical Announces Innovative Single Port Platform — the da Vinci SP® Surgical System 

The da Vinci SP system
image79

 Intuitive Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies 

Da Vinci by Intuitive
image80

 Intuitive Surgical Receives FDA Clearance for First 60mm Stapler 

SureForm 60™, a single-patient use 60mm stapler, offers 120 degrees of fully wristed articulation
image81

 New Study Shows Robotic-Assisted Surgery Benefits for Inguinal Hernia Repair 

da Vinci Surgical System
image82

 New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform 

Results from the first clinical study evaluating a new flexible robotics platform under development by Intuitive Surgical
image83

 Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System 

Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System